EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The TLR7 agonist vesatolimod does not measurably induce SIV expression in macaques receiving combination antiretroviral therapy initiated during chronic infection

Adrienne E Swanstrom, Kelli Oswald, Randy Fast iD, Rebecca Shoemaker, James A Thomas, Cathi Pyle, Michael Hull, William J Bosche, Yuan Li, Matthew W Breed iD, Joshua A Kramer, Duncan Donohue und 5 weitere

Antimicrobial Agents and Chemotherapy · 2025

DOI: 10.1128/aac.01073-25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2025. Verfasst von Adrienne E Swanstrom und 16 weiteren Autor:innen. Beteiligte Einrichtung: AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA. Hauptthemen laut MEDLINE: Toll-Like Receptor 7, Simian Acquired Immunodeficiency Syndrome, Simian Immunodeficiency Virus, Pteridines. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 77 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, CCR NIH HHS, NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lim et al. previously reported that TLR7 agonist (Vesatolimod [VES] or the related compound GS-986) administration to SIVmac251-infected macaques receiving combination antiretroviral therapy (cART) led to transient plasma viral load (PVL) increases, viral DNA (vDNA) reductions in blood and tissues, and, in some animals, extended viral remission after treatment cessation (S. Y. Lim, C. E. Osuna, P. T. Hraber, J. Hesselgesser, et al., Sci Transl Med 10:eaao4521, 2018, https://doi.org/10.1126/scitranslmed.aao4521 ). However, in multiple subsequent studies, TLR7 agonist administration in SIV or SHIV-infected macaques on cART did not induce measurable virus expression. Notably, these studies utilized earlier cART initiation, lengthier cART treatment before TLR7 agonist administration, different sampling time points, and/or less sensitive virologic assays compared to the Lim study. We hypothesized that study design and assay differences may have led to these apparently discrepant results due to quantitative or qualitative differences in the established viral reservoirs and/or a reduced capacity to detect virus induction. To more closely capture the Lim study conditions, we initiated cART at 65 days post-infection in 10 SIVmac239M-infected rhesus macaques. Six received VES (0.15 mg/kg orally, every 2 weeks for six doses), while four received vehicle control. Although VES treatment induced expected transient increases in interferon-stimulated gene expression and immune cell phenotypic changes, it did not lead to measurable PVL increases in peripheral or hepatic portal vein blood using a highly sensitive PVL assay or increases in cell-associated vRNA:vDNA ratios, nor to measurable reductions in vDNA in blood or tissues. These results align with recent clinical data and confirm that TLR7 agonist treatment does not reliably induce significant virus expression in vivo .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Toll-Like Receptor 7Simian Acquired Immunodeficiency SyndromeSimian Immunodeficiency VirusPteridinesAnti-Retroviral AgentsAnimalsViral LoadMacaca mulatta

Stichwörter der Autor:innen

HIV cureHIV latencyHIV-1SIVmacaquenonhuman primate

Substanzen

Toll-Like Receptor 7vesatolimodPteridinesAnti-Retroviral Agents

Autor:innen und Institutionen

  • AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA.
  • Laboratory Animal Sciences Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA.
  • Statistical Consulting and Scientific Programming Group, Computer and Statistical Services, Data Management Services, Inc, NCI-Frederick, Frederick, Maryland, USA.
  • Gilead Sciences, Foster City, California, USA.

ORCID-Profile: Randy Fast, Matthew W Breed, Claire Deleage, Romas Geleziunas, Jeffrey D Lifson, Gregory Q Del Prete

Förderung

  • NIAID NIH HHS
  • CCR NIH HHS
  • NCI NIH HHS
  • Gilead Sciences
  • National Cancer Institute

Zitieren

APA

Swanstrom, A. E., Oswald, K., Fast, R., Shoemaker, R., Thomas, J. A., Pyle, C., Hull, M., Bosche, W. J., Li, Y., Breed, M. W., Kramer, J. A., Donohue, D., Trubey, C. M., Deleage, C., Geleziunas, R., Lifson, J. D., & Del Prete, G. Q. (2025). The TLR7 agonist vesatolimod does not measurably induce SIV expression in macaques receiving combination antiretroviral therapy initiated during chronic infection. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01073-25

Vancouver

Swanstrom AE, Oswald K, Fast R, Shoemaker R, Thomas JA, Pyle C, et al. The TLR7 agonist vesatolimod does not measurably induce SIV expression in macaques receiving combination antiretroviral therapy initiated during chronic infection. Antimicrobial Agents and Chemotherapy. 2025. doi:10.1128/aac.01073-25

BibTeX
@article{Swanstrom2025,
  author = {Swanstrom, Adrienne E and Oswald, Kelli and Fast, Randy and Shoemaker, Rebecca and Thomas, James A and Pyle, Cathi and Hull, Michael and Bosche, William J and Li, Yuan and Breed, Matthew W and Kramer, Joshua A and Donohue, Duncan and Trubey, Charles M and Deleage, Claire and Geleziunas, Romas and Lifson, Jeffrey D and Del Prete, Gregory Q},
  title = {The TLR7 agonist vesatolimod does not measurably induce SIV expression in macaques receiving combination antiretroviral therapy initiated during chronic infection},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2025},
  doi = {10.1128/aac.01073-25}
}
Kostenlos starten →